Brief: FDA Grants Soligenix Orphan Drug Designation For The Prevention And Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Soligenix

15/04/2024 12:35

April 15 (Reuters) - Soligenix Inc  SNGX.O :
    * FDA GRANTS SOLIGENIX ORPHAN DRUG DESIGNATION FOR THE
PREVENTION
AND POST-EXPOSURE PROPHYLAXIS AGAINST MARBURG MARBURGVIRUS
INFECTION
    * SOLIGENIX INC: PROVIDES MARVAX™ HEAT STABLE VACCINE SEVEN
YEARS
OF U.S. MARKET EXCLUSIVITY UPON FDA APPROVAL

Source text for Eikon:  ID:nPn2Sn0XHa 
Further company coverage:  SNGX.O 

 ((Reuters.Briefs@thomsonreuters.com;))